Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survival
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Figure 1: Flow-chart of the subjects included in the study. *Most cases of BT were ovarian cystadenofibromas, leiomyomas, teratomas, fibrothecomas or various cysts which, after microscopical analysis of the biopsies, were shown to be nonmalignant. **Sixteen cases had received a treatment prior to the first coelioscopy or suffered a cancer within the two last years before the detection of the OvCa. Two patients were excluded, as the tumor was classified as borderline upon histopathological examination. Finally, 3 cases of ovarian tumors were proven to be the result of breast or colon cancer metastases. 
Introduction to Figure 2 -Selection of endogenous reference
Quantitative assessment of microRNAs by real-time PCR requires endogenous references to avoid biases due to RNA extraction and reverse transcription efficiency. Therefore, during preliminary studies, we investigated the potential of 3 miRNAs -hsa-miR-132-3p, hsa-miR23a-3p and hsa-miR-191-5p -already used for normalization of plasma microRNAs in published studies [1, 6] . Our main selection criteria were their detection at a substantial and consistent level among our 3 groups of plasma samples (HW, BT, OvCa). The consistency of their concentration was evaluated by comparison of the median Ct value using the KruskalWallis test. MiR-132 was rapidly eliminated because of being poorly detected in the majority of the control as well as OvCa subjects (data not shown). MiR-23a was readily detected in most plasma samples but was in fact dependent on the disease state (p-value = 0.036). In contrast, the average level of miR-191 was consistent in plasma samples from all 3 categories of donors (median values 31.91, 32.54 and 32.46 for HW, BT and OvCa respectively, p-value = 0.13). Therefore, miR-191 was chosen for data normalization (see Figure 2 below). 
